The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
Patients with rosacea and skin of color are more likely to have severe disease phenotypes when compared with White patients with rosacea.
Your skin holds vital clues about your health. From thyroid issues to heart problems, discover what your skin is trying to ...
Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...
India: A recent case report published in the Cureus Journal has highlighted the effectiveness of liquid nitrogen cryotherapy ...
Crohn’s disease can cause digestive issues However since it is an inflammatory disease the symptoms can go beyond the gut ...
Diagnosis of PDB is a combination of clinical evaluation, imaging and histopathological assessment. If an underlying cancer ...
When a 60-year-old woman with severe abdominal pain shows positive Carnett’s and pinch signs, physicians suspect ACNES — but ...
17h
News-Medical.Net on MSNViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIVViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.
The antibody tests available in the Netherlands are reliable, according to this doctoral research. However, it is important to test only in case of symptoms specific for Lyme disease and a real chance ...
According to Huynh, covering as much of the skin as possible when outdoors is the best defense against tick bites. However, ...
Arcutis Biotherapeutics (ARQT) announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting, AAD. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results